容量超负荷与射血分数降低心衰患者肾功能结局的关联
基于EVEREST试验3718例HFrEF患者数据,中位随访10个月,评估容量超负荷(BNP/NT-proBNP及临床充血评分)与eGFR下降>40%及新发CKD≥4期的关联。多因素校正后,最高四分位NT-proBNP者eGFR下降>40%风险HR=2.62,新发CKD≥4期风险HR=2.66;最高充血评分者对应风险分别增加48%和42%。
要点
- NT-proBNP最高四分位者eGFR下降>40%风险为最低四分位的2.62倍。
- NT-proBNP最高四分位者新发CKD≥4期风险为最低四分位的2.66倍。
- 临床充血评分最高四分位者eGFR下降>40%风险增加48%。
核心结论
- 容量超负荷(利钠肽升高及临床体征症状)与HFrEF患者临床重要肾功能结局风险增加相关。
研究设计与样本
- 基于EVEREST试验数据,纳入3718例HFrEF患者,平均eGFR 59±22 ml/min per 1.73 m2,中位随访10个月。
- 采用多变量Cox回归模型评估容量超负荷指标与eGFR下降>40%及新发CKD≥4期的关联。
主要发现
- 340例(9%)出现eGFR下降>40%,337例(10%)新发CKD≥4期。
- 与NT-proBNP最低四分位组相比,最高四分位组eGFR下降>40%的HR=2.62(95%CI 1.62, 4.23)。
- NT-proBNP最高四分位组新发CKD≥4期的HR=2.66(95%CI 1.49, 4.77),BNP呈相似趋势。
- 临床充血评分最高四分位组eGFR下降>40%的HR=1.48(95%CI 1.07, 2.06),新发CKD≥4期的HR=1.42(95%CI 1.01, 1.99)。
关键数值与推荐
- eGFR下降>40%定义为较基线eGFR下降超过40%。
- 新发CKD≥4期定义为eGFR<30 ml/min per 1.73 m2。
- 临床充血评分量表范围0-12分,由下肢水肿、颈静脉怒张、啰音和端坐呼吸组成。
临床怎么用
- 在HFrEF患者中,应关注利钠肽水平及临床充血体征以识别肾功能恶化高风险者。
- 容量超负荷可作为肾功能预后评估的辅助指标,提示需加强容量管理。
局限性
- 本研究为基于EVEREST试验数据的回顾性分析,结论需前瞻性研究验证。
- 容量超负荷与肾功能结局的关联可能受未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In patients with heart failure with reduced ejection fraction (HFrEF), volume overload is associated with mortality. Few studies that have examined the relation between volume and long-term kidney function outcomes in HFrEF. METHODS: Using data from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial, we used multivariable Cox regression models to evaluate the association between volume overload as evaluated by B-type natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP), and a clinical congestion score (scale of 0-12) composed of pedal edema, jugular venous distension, rales, and orthopnea with the occurrence of estimated glomerular filtration rate (eGFR) decline by >40%, and incident chronic kidney disease (CKD) stage ≥4 defined by eGFR of <30 ml/min per 1.73 m2, over a median 10-month follow-up. RESULTS: Among 3718 patients (mean eGFR 59 ± 22 ml/min per 1.73 m2), 340 (9%) reached an eGFR decline >40% and 337 (10%) developed incident CKD stage ≥4. In multivariable models, compared with those in the quartile of lowest NT-proBNP, those within the highest quartile had a significantly higher risk of eGFR decline by >40% (hazard ratio [HR] = 2.62 [95% confidence interval {CI} = 1.62, 4.23]) and incident CKD stage ≥4 (HR = 2.66 [95% CI = 1.49, 4.77]), with similar trends for BNP. Similarly in multivariable models, patients in the quartile of highest congestion score had a 48% increased risk for eGFR decline by >40% (HR = 1.48 [95% CI = 1.07, 2.06]) and a 42% increased risk for CKD stage ≥4 (HR = 1.42 [95% CI = 1.01, 1.99]), compared with the lowest quartile. CONCLUSION: Volume overload, as indicated both by elevated natriuretic peptides and clinical signs and symptoms, is associated with increased risk for clinically important kidney function outcomes in HFrEF.
引用
- McCallum W, Tighiouart H, Testani JM, et al. Association of Volume Overload With Kidney Function Outcomes Among Patients With Heart Failure With Reduced Ejection Fraction. Kidney Int Rep. 2020. PMID: 33102958. doi:10.1016/j.ekir.2020.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。